Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 15/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 15/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 15/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6711944 | 0.72 | MYLK (0.36) | ADRA1DADRA1AADRA1BPOLB | |
| SCHEMBL8330463 | 0.66 | CACNA1F (0.43) | ADRA1DADRA1AADRA1BTSHRNPSR1 | |
| SCHEMBL7660734 | 0.62 | ADRA1D (0.42) | ADRA1DADRA1AADRA1B | |
| SCHEMBL7272445 | 0.61 | MTOR (0.47) | — | |
| SCHEMBL5660976 | 0.60 | ALDH1A1 (0.32) | NPSR1 | |
| SCHEMBL8005453 | 0.60 | ALDH1A1 (0.32) | NPSR1 | |
| SCHEMBL9476150 | 0.60 | CACNA1C (0.53) | TSHRCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6946930 | 0.59 | ABCC9 (0.50) | — | |
| SCHEMBL823677 | 0.57 | CES2 (0.64) | NPSR1 | |
| SCHEMBL16431977 | 0.55 | ALDH1A1 (0.47) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720324-B2 | THERAPY FOR EATING DISORDERS, SEXUAL DISORDERS, PSYCHOLOGICAL DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-13 | — | — | US | disclosed |
| US-20040038855-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2004-02-26 | — | — | US | disclosed |
| US-20030069261-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | H. LUNDBECK A/S (DK) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038855-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | MCHR1, MCHR2, MC1R | ADRA1D 100/4885ADRA1A 88/4885ADRA1B 143/4885 |
| US-20030069261-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | MCHR1, MCHR2, MC4R | ADRA1D 149/4885ADRA1A 161/4885ADRA1B 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.